Introduction
============

The digitisation of society means we are amassing data at an unprecedented rate. Healthcare is no exception, with IBM estimating approximately one million gigabytes accruing over an average person's lifetime and the overall volume of global healthcare data doubling every few years.[@ref1] To make sense of these big data, clinicians are increasingly collaborating with computer scientists and other allied disciplines to make use of artificial intelligence (AI) techniques that can help detect signal from noise.[@ref2] A recent forecast has placed the value of the healthcare AI market as growing from \$2bn (£1.5bn; €1.8bn) in 2018 to \$36bn by 2025, with a 50% compound annual growth rate.[@ref3]

Deep learning is a subset of AI which is formally defined as "computational models that are composed of multiple processing layers to learn representations of data with multiple levels of abstraction."[@ref4] In practice, the main distinguishing feature between convolutional neural networks (CNNs) in deep learning and traditional machine learning is that when CNNs are fed with raw data, they develop their own representations needed for pattern recognition; they do not require domain expertise to structure the data and design feature extractors.[@ref5] In plain language, the algorithm learns for itself the features of an image that are important for classification rather than being told by humans which features to use. A typical example would be feeding in raw chest radiographs tagged with a label such as either pneumothorax or no pneumothorax and the CNN learning which pixel patterns suggest pneumothorax. Fields such as medical imaging have seen a growing interest in deep learning research, with more and more studies being published.[@ref6] Some media headlines that claim superior performance to doctors have fuelled hype among the public and press for accelerated implementation. Examples include: "Google says its AI can spot lung cancer a year before doctors" and "AI is better at diagnosing skin cancer than your doctor, study finds."[@ref7] [@ref8]

The methods and risk of bias of studies behind such headlines have not been examined in detail. The danger is that public and commercial appetite for healthcare AI outpaces the development of a rigorous evidence base to support this comparatively young field. Ideally, the path to implementation would involve two key steps. Firstly, well conducted and well reported development and validation studies that describe an algorithm and its properties in detail, including predictive accuracy in the target setting. Secondly, well conducted and transparently reported randomised clinical trials that evaluate usefulness in the real world. Both steps are important to ensure clinical practice is determined based on the best evidence standards.[@ref9] [@ref10] [@ref11] [@ref12]

Our systematic review seeks to give a contemporary overview of the current standards of deep learning research for clinical applications. Specifically, we sought to describe the study characteristics, and evaluate the methods and quality of reporting and transparency of deep learning studies that compare diagnostic algorithm performance with human clinicians. We aim to suggest how we can move forward in a way that encourages innovation while avoiding hype, diminishing research waste, and protecting patients.

Methods
=======

The protocol for this study was registered in the online PROSPERO database (CRD42019123605) before search execution. The supplementary appendix gives details of any deviations from the protocol. This manuscript has been prepared according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines and a checklist is available in the supplementary appendix.[@ref13]

Study identification and inclusion criteria
-------------------------------------------

We performed a comprehensive search by using free text terms for various forms of the keywords "deep learning" and "clinician" to identify eligible studies. Appendix 1 presents the exact search strategy. Several electronic databases were searched from 2010 to June 2019: Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and the World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP) search portal. Additional articles were retrieved by manually scrutinising the reference lists of relevant publications.

We selected publications for review if they satisfied several inclusion criteria: a peer reviewed scientific report of original research; English language; assessed a deep learning algorithm applied to a clinical problem in medical imaging; compared algorithm performance with a contemporary human group not involved in establishing the ground truth (the true target disease status verified by best clinical practice); and at least one human in the group was considered an expert. We included studies when the aim was to use medical imaging for predicting absolute risk of existing disease or classification into diagnostic groups (eg, disease or non-disease). Exclusion criteria included informal publication types (such as commentaries, letters to the editor, editorials, meeting abstracts). Deep learning for the purpose of medical imaging was defined as computational models that are composed of multiple processing layers to learn representations of data with multiple levels of abstraction (in practice through a CNN; see [box 1](#box1){ref-type="boxed-text"}).[@ref4] A clinical problem was defined as a situation in which a patient would usually see a medical professional to improve or manage their health (this did not include segmentation tasks, eg, delineating the borders of a tumour to calculate tumour volume). An expert was defined as an appropriately board certified specialist, attending physician, or equivalent. A real world clinical environment was defined as a situation in which the algorithm was embedded into an active clinical pathway. For example, instead of an algorithm being fed thousands of chest radiographs from a database, in a real world implementation it would exist within the reporting software used by radiologists and be acting or supporting the radiologists in real time.

###### Deep learning in imaging with examples

Deep learning is a subset of artificial intelligence that is formally defined as "computational models that are composed of multiple processing layers to learn representations of data with multiple levels of abstraction."[@ref4] A deep learning algorithm consists of a structure referred to as a deep neural network of which a convolutional neural network (CNN) is one particular type frequently used in imaging. CNNs are structurally inspired by the hierarchical arrangement of neurons within the brain. They can take many nuanced forms but the basic structure consists of an input layer, multiple hidden layers, and a final output layer. Each hidden layer responds to a different aspect of the raw input. In the case of imaging, this could be an edge, colour, or specific pattern.

The key difference between deep learning and other types of machine learning is that CNNs develop their own representations needed for pattern recognition rather than requiring human input to structure the data and design feature extractors. In plain language, the algorithm learns for itself the features of an image that are important for classification. Therefore, the algorithm has the freedom to discover classification features that might not have been apparent to humans (particularly when datasets are large) and thereby improve the performance of image classification.

CNNs use raw image data that have been labelled by humans in a process known as supervised learning. Each image is fed into the input layer of the algorithm as raw pixels and then processed sequentially through the layers of the CNN. The final output is a classification likelihood of the image belonging to a prespecified group.

Some examples from this review include the following:

-   Feeding in raw chest radiographs tagged with a label (pneumothorax or no pneumothorax) and the CNN learning which pixel patterns suggest pneumothorax. When fed with new untagged images, the CNN outputs a likelihood of the new image containing a pneumothorax or not.

-   Feeding in raw retinal images tagged with the stage of age related macular degeneration and the CNN learning which pixel patterns suggest a particular stage. When fed with new untagged images, the CNN outputs a likelihood of the new image containing a specific stage of age related macular degeneration.

-   Feeding in optical coherence tomography scans tagged with a management decision (urgent referral, semi urgent referral, routine referral, observation). When fed with new untagged images, the CNN outputs a likelihood of the most appropriate management decision.

Study selection and extraction of data
--------------------------------------

After removal of clearly irrelevant records, four people (MN, YC, CAL, Dina Radenkovic) independently screened abstracts for potentially eligible studies so that each record was reviewed by at least two people. Full text reports were then assessed for eligibility with disagreements resolved by consensus. At least two people (MN, YC, CAL) extracted data from study reports independently and in duplicate for each eligible study, with disagreements resolved by consensus or a third reviewer.

Adherence to reporting standards and risk of bias
-------------------------------------------------

We assessed reporting quality of non-randomised studies against a modified version of the TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) statement.[@ref14] This statement aims to improve the transparent reporting of prediction modelling studies of all types and in all medical settings.[@ref15] The TRIPOD statement consists of a 22 item checklist (37 total points when all subitems are included), but we considered some items to be less relevant to deep learning studies (eg, points that related to predictor variables). Deep learning algorithms can consider multiple predictors; however, in the cases we assessed, the only predictors (almost exclusively) were the individual pixels of the image. The algorithm did not typically receive information on characteristics such as patient age, sex, and medical history. Therefore, we used a modified list of 29 total points (see appendix 2). The aim was to assess whether studies broadly conformed to reporting recommendations included in TRIPOD, and not the detailed granularity required for a full assessment of adherence.[@ref16]

We assessed risk of bias for non-randomised studies by applying PROBAST (prediction model risk of bias assessment tool).[@ref17] PROBAST contains 20 signalling questions from four domains (participants, predictors, outcomes, and analysis) to allow assessment of the risk of bias in predictive modelling studies.[@ref18] We did not assess applicability (because no specific therapeutic question existed for this systematic review) or predictor variables (these are less relevant in deep learning studies on medical imaging; see appendix 2).

We assessed the broad level reporting of randomised studies against the CONSORT (consolidated standards of reporting trials) statement. Risk of bias was evaluated by applying the Cochrane risk of bias tool.[@ref11] [@ref19]

Data synthesis
--------------

We intentionally planned not to conduct formal quantitative syntheses because of the probable heterogeneity of specialties and outcomes.

Patient and public involvement
------------------------------

Patients were not involved in any aspect of the study design, conduct or in the development of the research question or outcome measures.

Results
=======

Study selection
---------------

Our electronic search, which was last updated on 17 June 2019, retrieved 8302 records (7334 study records and 968 trial registrations; see [fig 1](#f1){ref-type="fig"}). Of the 7334 study records, we assessed 140 full text articles; 59 were excluded, which left 81 non-randomised studies for analysis. Of the 968 trial registrations, we assessed 96 in full; 86 were excluded, which left 10 trial registrations that related to deep learning.

![PRISMA (preferred reporting items for systematic reviews and meta-analyses) flowchart of study records](nagm052733.f1){#f1}

Randomised clinical trials
--------------------------

[Table 1](#tbl1){ref-type="table"} summarises the 10 trial registrations. Eight related to gastroenterology, one to ophthalmology, and one to radiology. Eight were from China, one was from the United States, and one from Taiwan. Two trials have completed and published their results (both in 2019), three are recruiting, and five are not yet recruiting.

###### 

Randomised trial registrations of deep learning algorithms

  Trial registration    Title                                                                                                                                                            Status                 Record last updated   Country   Specialty          Planned sample size   Intervention                                        Control                              Blinding                                      Primary outcome                                   Anticipated completion
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- --------------------- --------- ------------------ --------------------- --------------------------------------------------- ------------------------------------ --------------------------------------------- ------------------------------------------------- ------------------------
  ChiCTR-DDD-17012221   A colorectal polyps auto-detection system based on deep learning to increase polyp detection rate: a prospective clinical study                                  Completed, published   16 July 2018          China     Gastroenterology   1000                  AI assisted colonoscopy                             Standard colonoscopy                 None                                          Polyp detection rate and adenoma detection rate   28 Feb 18
  NCT03240848           Comparison of artificial intelligent clinic and normal clinic                                                                                                    Completed, published   30 July 20 18         China     Ophthalmology      350                   AI assisted clinic                                  Normal clinic                        Double (investigator and outcomes assessor)   Accuracy for congenital cataracts                 25 May 18
  NCT03706534           Breast ultrasound image reviewed with assistance of deep learning algorithms                                                                                     Recruiting             17 October 2018       US        Radiology          300                   Computer aided detection system                     Manual ultrasound imaging review     Double (participant and investigator)         Concordance rate                                  31 Jul 19
  NCT03840590           Adenoma detection rate using AI system in China                                                                                                                  Not yet recruiting     15 February 2019      China     Gastroenterology   800                   CSK AI system assisted colonoscopy                  Standard colonoscopy                 None                                          Adenoma detection rate                            01 Mar 20
  NCT03842059           Computer-aided detection for colonoscopy                                                                                                                         Not yet recruiting     15 February 2019      Taiwan    Gastroenterology   1000                  Computer aided detection                            Standard colonoscopy                 Double (participant, care provider)           Adenoma detection rate                            31 Dec 21
  ChiCTR1800017675      The impact of a computer aided diagnosis system based on deep learning on increasing polyp detection rate during colonoscopy, a prospective double blind study   Not yet recruiting     21 February 2019      China     Gastroenterology   1010                  AI assisted colonoscopy                             Standard colonoscopy                 Double                                        Polyp detection rate and adenoma detection rate   31 Jan 19
  ChiCTR1900021984      A multicenter randomised controlled study for evaluating the effectiveness of artificial intelligence in improving colonoscopy quality                           Recruiting             19 March 2019         China     Gastroenterology   1320                  EndoAngel assisted colonoscopy                      Colonoscopy                          Double (participants and evaluators)          Polyp detection rate                              31 Dec 20
  NCT03908645           Development and validation of a deep learning algorithm for bowel preparation quality scoring                                                                    Not yet recruiting     09 April 2019         China     Gastroenterology   100                   AI assisted scoring group                           Conventional human scoring group     Single (outcome assessor)                     Adequate bowel preparation                        15 Apr 20
  NCT03883035           Quality measurement of esophagogastroduodenoscopy using deep learning models                                                                                     Recruiting             17 April 2019         China     Gastroenterology   559                   DCNN model assisted EGD                             Conventional EGD                     Double (participant, care provider)           Detection of upper gastrointestinal lesions       20 May 20
  ChiCTR1900023282      Prospective clinical study for artificial intelligence platform for lymph node pathology detection of gastric cancer                                             Not yet recruiting     20 May 2019           China     Gastroenterology   60                    Pathological diagnosis of artificial intelligence   Traditional pathological diagnosis   Not stated                                    Clinical prognosis                                31 Aug 21

AI=artificial intelligence; CSK=commonsense knowledge; DCNN=deep convolutional neural network; EGD=esophagogastroduodenoscopy.**\[AU: please check definitions\]**

The first completed trial enrolled 350 paediatric patients who attended ophthalmology clinics in China. These patients underwent cataract assessment with or without an AI platform (using deep learning) to diagnose and provide a treatment recommendation (surgery or follow-up).[@ref20] The authors found that accuracy (defined as proportion of true results) of cataract diagnosis and treatment recommendation with AI were 87% (sensitivity 90%, specificity 86%) and 71% (sensitivity 87%, specificity 44%), respectively. These results were significantly lower than accuracy of diagnosis (99%, sensitivity 98%, specificity 99.6%) and treatment recommendation (97%, sensitivity 95%, specificity 100%) by senior consultants (P\<0.001 for both); and also lower than the results for the same AI when tested in a non-randomised clinical trial setting (98% and 93%, respectively). The mean time for receiving a diagnosis with the AI platform was faster than diagnosis by consultants (2.8 *v* 8.5 minutes, P\<0.001). The authors suggested that this might explain why patients were more satisfied with AI (mean satisfaction score 3.47 *v* 3.38, P=0.007). Risk of bias was low in all domains except for blinding of participants and personnel. The reporting showed high adherence (31 of 37 items, 84%) to the CONSORT checklist (which was included with the manuscript).

The second completed trial enrolled 1058 patients who underwent a colonoscopy with or without the assistance of a real time automatic polyp detection system, which provided simultaneous visual and sound alerts when it found a polyp.[@ref21] The authors reported that the detection system resulted in a significant increase in the adenoma detection rate (29% *v* 20%, P\<0.001), and an increase in the number of hyperplastic polyps identified (114 *v* 52, P\<0.001). Risk of bias was low in all domains except for blinding of participants, personnel, and outcome assessors. One of the other trial registrations belongs to the same author group. These authors are performing a double blind randomised clinical trial with sham AI to overcome the blinding issue in the previous study. The reporting showed high adherence (30 of 37 items, 81%) to the CONSORT checklist (though the CONSORT checklist itself was not included or referenced by the manuscript).

Non-randomised studies
----------------------

### General characteristics

[Table 2](#tbl2){ref-type="table"} and [table 3](#tbl3){ref-type="table"} summarise the basic characteristics of the 81 non-randomised studies. Nine of 81 (11%) non-randomised studies were prospective, but only six of these nine were tested in a real world clinical environment. The US and Asia accounted for 82% of studies, with the top four countries as follows: US (24/81, 30%), China (14/81, 17%), South Korea (12/81, 15%), and Japan (9/81, 11%). The top five specialties were radiology (36/81, 44%), ophthalmology (17/81, 21%), dermatology (9/81, 11%), gastroenterology (5/81, 6%), and histopathology (5/81, 6%). Eighteen (22%) studies compared how long a task took in AI and human arms in addition to accuracy or performance metrics. Funding was predominantly academic (47/81, 58%) as opposed to commercial (9/81, 11%) or mixed (1/81, 1%). Twelve studies stated they had no funding and another 12 did not report on funding. A detailed table with further information on the 81 studies is included as an online supplementary file.

###### 

Characteristics of non-randomised studies

  Lead author          Year   Country             Study type               Specialty          Disease                             Outcome                                                             Caveat in discussion\*   Suggestion in discussion†
  -------------------- ------ ------------------- ------------------------ ------------------ ----------------------------------- ------------------------------------------------------------------- ------------------------ ---------------------------
  Abramoff             2018   US                  Prospective real world   Ophthalmology      Diabetic retinopathy                More than mild diabetic retinopathy                                 No                       Yes
  Arbabshirani         2018   US                  Prospective real world   Radiology          Intracranial haemorrhage            Haemorrhage                                                         Yes                      No
  Arji                 2018   Japan               Retrospective            Radiology          Oral cancer                         Cervical lymph node metastases                                      No                       No
  Becker               2017   Switzerland         Retrospective            Radiology          Breast cancer                       BI-RADS category 5                                                  Yes                      No
  Becker               2018   Switzerland         Retrospective            Radiology          Breast cancer                       BI-RADS category 5                                                  Yes                      No
  Bien                 2018   US                  Retrospective            Radiology          Knee injuries                       Abnormality on MRI                                                  No                       No
  Brinker              2019   Germany             Retrospective            Dermatology        Skin cancer                         Melanoma                                                            No                       No
  Brinker              2019   Germany             Retrospective            Dermatology        Skin cancer                         Melanoma                                                            Yes                      No
  Brown                2018   US                  Retrospective            Ophthalmology      Retinopathy of prematurity          Plus disease                                                        No                       No
  Burlina              2018   US                  Retrospective            Ophthalmology      Macular degeneration                ARMD stage                                                          No                       No
  Burlina              2017   US                  Retrospective            Ophthalmology      Macular degeneration                Intermediate or advanced stage ARMD                                 No                       No
  Burlina              2017   US                  Retrospective            Ophthalmology      Macular degeneration                ARMD stage                                                          No                       No
  Bychov               2018   Finland             Retrospective            Histopathology     Colorectal cancer                   Low or high risk for 5 year survival                                No                       No
  Byra                 2018   US                  Retrospective            Radiology          Breast cancer                       BI-RADS category 4 or more                                          No                       No
  Cha                  2018   US                  Retrospective            Radiology          Bladder cancer                      T0 status post chemotherapy                                         No                       No
  Cha                  2019   South Korea         Retrospective            Radiology          Lung cancer                         Nodule operability                                                  Yes                      No
  Chee                 2019   South Korea         Retrospective            Radiology          Osteonecrosis of the femoral head   Stage of osteonecrosis                                              Yes                      No
  Chen                 2018   Taiwan              Prospective              Gastroenterology   Colorectal cancer                   Neoplastic polyp                                                    No                       No
  Choi                 2018   South Korea         Retrospective            Radiology          Liver fibrosis                      Fibrosis stage                                                      No                       No
  Choi                 2019   South Korea         Retrospective            Radiology          Breast cancer                       Malignancy                                                          No                       No
  Chung                2018   South Korea         Retrospective            Orthopaedics       Humerus fractures                   Proximal humerus fracture                                           Yes                      No
  Ciompi               2017   Netherlands/Italy   Retrospective            Radiology          Lung cancer                         Nodule type                                                         No                       No
  Ciritsis             2019   Switzerland         Retrospective            Radiology          Breast cancer                       BI-RADS stage                                                       No                       No
  De Fauw              2018   UK                  Retrospective            Ophthalmology      Retinopathy                         Diagnosis and referral decision                                     Yes                      No
  Ehtesham Bejnordii   2017   Netherlands         Retrospective            Histopathology     Breast cancer                       Metastases                                                          Yes                      No
  Esteva               2017   US                  Retrospective            Dermatology        Skin cancer                         Lesion type                                                         Yes                      No
  Fujioka              2019   Japan               Retrospective            Radiology          Breast cancer                       BI-RADS malignancy                                                  No                       No
  Fujisawa             2018   Japan               Retrospective            Dermatology        Skin cancer                         Malignancy classification                                           Yes                      No
  Gan                  2019   China               Retrospective            Orthopaedics       Wrist fractures                     Fracture                                                            Yes                      No
  Gulshan              2019   India               Prospective real world   Ophthalmology      Retinopathy                         Moderate or worse diabetic retinopathy or referable macula oedema   Yes                      No
  Haenssle             2018   Germany             Retrospective            Dermatology        Skin cancer                         Malignancy classification and management decision                   Yes                      No
  Hamm                 2019   US                  Retrospective            Radiology          Liver cancer                        LI-RADS category                                                    No                       No
  Han                  2018   South Korea         Retrospective            Dermatology        Skin cancer                         Cancer type                                                         No                       No
  Han                  2018   South Korea         Retrospective            Dermatology        Onchomycosis                        Onchomycosis diagnosis                                              No                       No
  Hannun               2019   US                  Retrospective            Cardiology         Arrhythmia                          Arrhythmia classification                                           No                       No
  He                   2019   China               Retrospective            Radiology          Bone cancer                         Recurrence of giant cell tumour                                     No                       No
  Hwang                2019   Taiwan              Retrospective            Ophthalmology      Macular degeneration                Classification and type of ARMD                                     No                       Yes
  Hwang                2018   South Korea         Retrospective            Radiology          Tuberculosis                        TB presence                                                         Yes                      No
  Hwang                2019   South Korea         Retrospective            Radiology          Pulmonary pathology                 Abnormal chest radiograph                                           Yes                      No
  Kim                  2018   South Korea         Retrospective            Radiology          Sinusitis                           Maxillary sinusitis label                                           No                       No
  Kise                 2019   Japan               Retrospective            Radiology          Sjogren's syndrome                  Sjogren's syndrome presence                                         No                       No
  Kooi                 2017   Netherlands         Retrospective            Radiology          Breast cancer                       Classification of mammogram                                         No                       No
  Krause               2018   US                  Retrospective            Ophthalmology      Diabetic retinopathy                Diabetic retinopathy stage                                          No                       No
  Kuo                  2019   Taiwan              Retrospective            Nephrology         Chronic kidney disease              eGFR\<60 mL/min/1.73m^2^                                            No                       Yes
  Lee                  2018   US                  Prospective              Radiology          Intracranial haemorrhage            Haemorrhage                                                         Yes                      No
  Li                   2018   China               Prospective              oncology           Nasopharyngeal cancer               Malignancy                                                          No                       Yes
  Li                   2018   China               Retrospective            Ophthalmology      Glaucoma                            Glaucoma                                                            No                       No
  Li                   2018   China               Retrospective            Radiology          Thyroid cancer                      Malignancy                                                          Yes                      No

ARMD=age related macular degeneration; BI-RADS=breast imaging reporting and data system; eGFR=estimated glomerular filtration rate; LI-RADS=liver imaging reporting and data system; MRI=magnetic resonance imaging; TB=tuberculosis.

Caveat mentioned in discussion about need for further prospective work or trials.

Suggestion in discussion that algorithm can now be used clinically.

###### 

Characteristics of non-randomised studies

  Lead author      Year   Country       Study type               Specialty          Disease                                       Outcome                                                               Caveat in discussion\*   Suggestion in discussion†
  ---------------- ------ ------------- ------------------------ ------------------ --------------------------------------------- --------------------------------------------------------------------- ------------------------ ---------------------------
  Long             2017   China         Prospective real world   Ophthalmology      Congenital cataracts                          Detection of congenital cataracts                                     No                       No
  Lu               2018   China         Retrospective            Ophthalmology      Macular pathologies                           Classification of macular pathology                                   No                       No
  Marchetti        2017   US            Retrospective            Dermatology        Skin cancer                                   Malignancy (melanoma)                                                 Yes                      No
  Matsuba          2018   Japan         Retrospective            Ophthalmology      Macular degeneration                          Wet AMD                                                               No                       No
  Mori             2018   Japan         Prospective real world   Gastroenterology   Polyps                                        Neoplastic polyp                                                      Yes                      Yes
  Nagpal           2019   US            Retrospective            Histopathology     Prostate cancer                               Gleason score                                                         No                       No
  Nakagawa         2019   Japan         Retrospective            Gastroenterology   Oesophageal cancer                            Cancer invasion depth stage SM2/3                                     No                       No
  Nam              2018   South Korea   Retrospective            Radiology          Pulmonary nodules                             Classification and localisation of nodule                             Yes                      No
  Nirschl          2018   US            Retrospective            Histopathology     Heart failure                                 Heart failure (pathologically)                                        No                       Yes
  Olczak           2017   Sweden        Retrospective            Orthopaedics       Fractures                                     Fracture                                                              No                       Yes
  Park             2019   US            Retrospective            Radiology          Cerebral aneurysm                             Aneurysm presence                                                     Yes                      No
  Poedjiastoeti    2018   Thailand      Retrospective            Oncology           Jaw tumours                                   Malignancy                                                            No                       No
  Rajpurkar        2018   US            Retrospective            Radiology          Pulmonary pathology                           Classification of chest radiograph pathology                          Yes                      No
  Raumviboonsuk    2019   Thailand      Prospective real world   Ophthalmology      Diabetic retinopathy                          Moderate or worse diabetic retinopathy                                Yes                      No
  Rodriguez-Ruiz   2018   Netherlands   Retrospective            Radiology          Breast cancer                                 Classification of mammogram                                           Yes                      No
  Sayres           2019   US            Retrospective            Ophthalmology      Diabetic retinopathy                          Moderate or worse non-proliferative diabetic retinopathy              No                       No
  Shichijo         2017   Japan         Retrospective            Gastroenterology   Gastritis                                     *Helicobacter pylori* gastritis                                       No                       No
  Singh            2018   US            Retrospective            Radiology          Pulmonary pathology                           Chest radiograph abnormality                                          No                       No
  Steiner          2018   US            Retrospective            Histopathology     Breast cancer                                 Metastases                                                            Yes                      No
  Ting             2017   Singapore     Retrospective            Ophthalmology      Retinopathy, glaucoma, macular degeneration   Referable pathology for retinopathy, glaucoma, macular degeneration   Yes                      No
  Urakawa          2019   Japan         Retrospective            Orthopaedics       Hip fractures                                 Intertrochanteric hip fracture                                        No                       No
  van Grinsven     2016   Netherlands   Retrospective            Ophthalmology      Fundal haemorrhage                            Fundal haemorrhage                                                    No                       No
  Walsh            2018   UK/Italy      Retrospective            Radiology          Fibrotic lung disease                         Fibrotic lung disease                                                 No                       No
  Wang             2019   China         Retrospective            Radiology          Thyroid nodule                                Nodule presence                                                       Yes                      No
  Wang             2018   China         Retrospective            Radiology          Lung cancer                                   Invasive or preinvasive adenocarcinoma nodule                         No                       No
  Wu               2019   US            Retrospective            Radiology          Bladder cancer                                T0 response to chemotherapy                                           No                       No
  Xue              2017   China         Retrospective            Orthopaedics       Hip osteoarthritis                            Radiograph presence of hip osteoarthritis                             No                       No
  Ye               2019   China         Retrospective            Radiology          Intracranial haemorrhage                      Presence of intracranial haemorrhage                                  Yes                      No
  Yu               2018   South Korea   Retrospective            Dermatology        Skin cancer                                   Malignancy (melanoma)                                                 No                       No
  Zhang            2019   China         Retrospective            Radiology          Pulmonary nodules                             Presence of a malignant nodule                                        Yes                      No
  Zhao             2018   China         Retrospective            Radiology          Lung cancer                                   Classification of nodule invasiveness                                 No                       No
  Zhu              2019   China         Retrospective            Gastroenterology   Gastric cancer                                Tumour invasion depth (deeper than SM1)                               No                       No
  Zucker           2019   US            Retrospective            Radiology          Cystic fibrosis                               Brasfield score                                                       Yes                      No

AMD=age related macular degeneration.

Caveat mentioned in discussion about need for further prospective work or trials.

Suggestion in discussion that algorithm can now be used clinically.

In 77 of 81 studies, a specific comment was included in the abstract about the comparison between AI and clinician performance. AI was described as superior in 23 (30%), comparable or better in 13 (17%), comparable in 25 (32%), able to help a clinician perform better in 14 (18%), and not superior in two (3%). Only nine studies added a caveat in the abstract that further prospective trials were required (this was missing in all 23 studies that reported AI was superior to clinician performance). Even in the discussion section of the paper, a call for prospective studies (or trials in the case of existing prospective work) was only made in 31 of 81 (38%) studies. Seven of 81 (9%) studies claimed in the discussion that the algorithm could now be used in clinical practice despite only two of the seven having been tested prospectively in a real world setting. Concerning reproducibility, data were public and available in only four studies (5%). Code (for preprocessing of data and modelling) was available in only six studies (7%). Both raw labelled data and code were available in only one study.[@ref22]

### Methods and risk of bias

Most studies developed and validated a model (63/81, 78%) compared with development only by using validation through resampling (9/81, 11%) or validation only (9/81, 11%). When validation occurred in a separate dataset, this dataset was from a different geographical region in 19 of 35 (54%) studies, from a different time period in 11 of 35 (31%), and a combination of both in five of 35 (14%). In studies that did not use a separate dataset for validation, the most common method of internal validation was split sample (29/37) followed by cross validation (15/37), and then bootstrapping (6/37); some studies used more than one method ([box 2](#box2){ref-type="boxed-text"}). Sample size calculations were reported in 14 of 81 (17%) studies. Dataset sizes were as follows (when reported): training, median 2678 (interquartile range 704-21 362); validation, 600 (200-1359); and test, 337 (144-891). The median event rate for development, validation, and test sets was 42%, 44%, and 44%, respectively, when a binary outcome was assessed (n=62) as opposed to a multiclass classification (n=19). Forty one of 81 studies used data augmentation (eg, flipping and inverting images) to increase the dataset size.

###### Specific terms

1.  Internal validation: evaluation of model performance with data used in development process

2.  External validation: evaluation of model performance with separate data not used in development process

3.  Cross validation: internal validation approach in which data are randomly split into n equally sized groups; the model is developed in n−1 of n groups, and performance evaluated in the remaining group with the whole process repeated n times; model performance is taken as average over n iterations

4.  Bootstrapping: internal validation approach similar to cross validation but relying on random sampling with replacement; each sample is the same size as model development dataset

5.  Split sample: internal validation approach in which the available development dataset is divided into two datasets: one to develop the model and the other to validate the model; division can be random or non-random.

The human comparator group was generally small and included a median of five clinicians (interquartile range 3-13, range 1-157), of which a median of four were experts (interquartile range 2-9, range 1-91). The number of participating non-experts varied from 0 to 94 (median 1, interquartile range 0-3). Experts were used exclusively in 36 of 81 studies, but in the 45 studies that included non-experts, 41 had separate performance data available which were exclusive to the expert group. In most studies, every human (expert or non-expert) rated the test dataset independently (blinded to all other clinical information except the image in 33/81 studies). The volume and granularity of the separate data for experts varied considerably among studies, with some reporting individual performance metrics for each human (usually in supplementary appendices).

The overall risk of bias assessed using PROBAST led to 58 of 81 (72%) studies being classified as high risk ([fig 2](#f2){ref-type="fig"}); the analysis domain was most commonly rated to be at high risk of bias (as opposed to participant or outcome ascertainment domains). Major deficiencies in the analysis domain related to PROBAST items 4.1 (were there a reasonable number of participants?), 4.3 (were all enrolled participants included in the analysis?), 4.7 (were relevant model performance measures evaluated appropriately?), and 4.8 (were model overfitting and optimism in model performance accounted for?).

![PROBAST (prediction model risk of bias assessment tool) risk of bias assessment for non-randomised studies](nagm052733.f2){#f2}

### Adherence to reporting standards

Adherence to reporting standards was poor (\<50% adherence) for 12 of 29 TRIPOD items (see [fig 3](#f3){ref-type="fig"}). Overall, publications adhered to between 24% and 90% of the TRIPOD items: median 62% (interquartile range 45-69%). Eight TRIPOD items were reported in 90% or more of the 81 studies, and five items in less than 30% ([fig 3](#f3){ref-type="fig"}). A flowchart for the flow of patients or data through the study was only present in 25 of 81 (31%) studies. We also looked for reporting of the hardware that was used for developing or validating the algorithm, although this was not specifically requested in the TRIPOD statement. Only 29 of 81 (36%) studies reported this information and in most cases (n=18) it related only to the graphics processing unit rather than providing full details (eg, random access memory, central processing unit speed, configuration settings etc.).

![Completeness of reporting of individual TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) items for non-randomised studies](nagm052733.f3){#f3}

Discussion
==========

We have conducted an appraisal of the methods, adherence to reporting standards, risk of bias, and claims of deep learning studies that compare diagnostic AI performance with human clinicians. The rapidly advancing nature and commercial drive of this field has created pressure to introduce AI algorithms into clinical practice as quickly as possible. The potential consequences for patients of this implementation without a rigorous evidence base make our findings timely and should guide efforts to improve the design, reporting, transparency, and nuanced conclusions of deep learning studies.[@ref23] [@ref24]

Principal findings
------------------

Five key findings were established from our review. Firstly, we found few relevant randomised clinical trials (ongoing or completed) of deep learning in medical imaging. While time is required to move from development to validation to prospective feasibility testing before conducting a trial, this means that claims about performance against clinicians should be tempered accordingly. However, deep learning only became mainstream in 2014, giving a lead time of approximately five years for testing within clinical environments, and prospective studies could take a minimum of one to two years to conduct. Therefore, it is reasonable to assume that many similar trials will be forthcoming over the next decade. We found only one randomised trial registered in the US despite at least 16 deep learning algorithms for medical imaging approved for marketing by the Food and Drug Administration (FDA). These algorithms cover a range of fields from radiology to ophthalmology and cardiology.[@ref2] [@ref25]

Secondly, of the non-randomised studies, only nine were prospective and just six were tested in a real world clinical environment. Comparisons of AI performance against human clinicians are therefore difficult to evaluate given the artificial in silico context in which clinicians are being evaluated. In much the same way that surrogate endpoints do not always reflect clinical benefit,[@ref26] a higher area under the curve might not lead to clinical benefit and could even have unintended adverse effects. Such effects could include an unacceptably high false positive rate, which is not apparent from an in silico evaluation. Yet it is typically retrospective studies that are usually cited in FDA approval notices for marketing of algorithms. Currently, the FDA do not mandate peer reviewed publication of these studies; instead internal review alone is performed.[@ref27] [@ref28] However, the FDA has recognised and acknowledged that their traditional paradigm of medical device regulation was not designed for adaptive AI and machine learning technologies. Non-inferior AI (rather than superior) performance that allows for a lower burden on clinician workflow (that is, being quicker with similar accuracy) might warrant further investigation. However, less than a quarter of studies reported time taken for task completion in both the AI and human groups. Ensuring fair comparison between AI and clinicians is arguably done best in a randomised clinical trial (or at the very least prospective) setting. However, it should be noted that prospective testing is not necessary to actually develop the model in the first place. Even in a randomised clinical trial setting, ensuring that functional robustness tests are present is crucial. For example, does the algorithm produce the correct decision for normal anatomical variants and is the decision independent of the camera or imaging software used?

Thirdly, limited availability of datasets and code makes it difficult to assess the reproducibility of deep learning research. Descriptions of the hardware used, when present, were also brief and this vagueness might affect external validity and implementation. Reproducible research has become a pressing issue across many scientific disciplines and efforts to encourage data and code sharing are crucial.[@ref29] [@ref30] [@ref31] Even when commercial concerns exist about intellectual property, strong arguments exist for ensuring that algorithms are non-proprietary and available for scrutiny.[@ref32] Commercial companies could collaborate with non-profit third parties for independent prospective validation.

Fourthly, the number of humans in the comparator group was typically small with a median of only four experts. There can be wide intra and inter case variation even between expert clinicians. Therefore, an appropriately large human sample for comparison is essential for ensuring reliability. Inclusion of non-experts can dilute the average human performance and potentially make the AI algorithm look better than it otherwise might. If the algorithm is designed specifically to aid performance of more junior clinicians or non-specialists rather than experts, then this should be made clear.

Fifthly, descriptive phrases that suggested at least comparable (or better) diagnostic performance of an algorithm to a clinician were found in most abstracts, despite studies having overt limitations in design, reporting, transparency, and risk of bias. Caveats about the need for further prospective testing were rarely mentioned in the abstract (and not at all in the 23 studies that claimed superior performance to a clinician). Accepting that abstracts are usually word limited, even in the discussion sections of the main text, nearly two thirds of studies failed to make an explicit recommendation for further prospective studies or trials. One retrospective study gave a website address in the abstract for patients to upload their eye scans and use the algorithm themselves.[@ref33] Overpromising language leaves studies vulnerable to being misinterpreted by the media and the public. Although it is clearly beyond the power of authors to control how the media and public interpret their findings, judicious and responsible use of language in studies and press releases that factor in the strength and quality of the evidence can help.[@ref34] This issue is especially concerning given the findings from new research that suggests patients are more likely to consider a treatment beneficial when news stories are reported with spin, and that false news spreads much faster online than true news.[@ref35] [@ref36]

Policy implications
-------------------

The impetus for guiding best practice has gathered pace in the last year with the publication of a report that proposes a framework for developing transparent, replicable, ethical, and effective research in healthcare AI (AI-TREE).[@ref37] This endeavour is led by a multidisciplinary team of clinicians, methodologists, statisticians, data scientists, and healthcare policy makers. The guiding questions of this framework will probably feed into the creation of more specific reporting standards such as a TRIPOD extension for machine learning studies.[@ref38] Key to the success of these efforts will be high visibility to researchers and possibly some degree of enforcement by journals in a similar vein to preregistering randomised trials and reporting them according to the CONSORT statement.[@ref11] [@ref39] Enthusiasm exists to speed up the process by which medical devices that feature AI are approved for marketing.[@ref40] [@ref41] Better design and more transparent reporting should be seen eventually as a facilitator of the innovation, validation, and translation process, and could help avoid hype.

Study limitations
-----------------

Our findings must be considered in light of several limitations. Firstly, although comprehensive, our search might have missed some studies that could have been included. Secondly, the guidelines that we used to assess non-randomised studies (TRIPOD and PROBAST) were designed for conventional prediction modelling studies, and so the adherence levels we found should be interpreted in this context. Thirdly, we focused specifically on deep learning for diagnostic medical imaging. Therefore, it might not be appropriate to generalise our findings to other types of AI, such as conventional machine learning (eg, an artificial neural network based mortality prediction model that uses electronic health record data). Similar issues could exist in many other types of AI paper, however we cannot definitively make this claim from our findings because we only assessed medical imaging studies. Moreover, nomenclature in the field is sometimes used in non-standardised ways, and thus some potentially eligible studies might have been presented with terminology that did not lead to them being captured with our search strategy. Fourthly, risk of bias entails some subjective judgment and people with different experiences of AI performance could have varying perceptions.

Conclusions
-----------

Deep learning AI is an innovative and fast moving field with the potential to improve clinical outcomes. Financial investment is pouring in, global media coverage is widespread, and in some cases algorithms are already at marketing and public adoption stage. However, at present, many arguably exaggerated claims exist about equivalence with or superiority over clinicians, which presents a risk for patient safety and population health at the societal level, with AI algorithms applied in some cases to millions of patients. Overpromising language could mean that some studies might inadvertently mislead the media and the public, and potentially lead to the provision of inappropriate care that does not align with patients' best interests. The development of a higher quality and more transparently reported evidence base moving forward will help to avoid hype, diminish research waste, and protect patients.

### What is already known on this topic

1.  The volume of published research on deep learning, a branch of artificial intelligence (AI), is rapidly growing

2.  Media headlines that claim superior performance to doctors have fuelled hype among the public and press for accelerated implementation

### What this study adds

1.  Few prospective deep learning studies and randomised trials exist in medical imaging

2.  Most non-randomised trials are not prospective, are at high risk of bias, and deviate from existing reporting standards

3.  Data and code availability are lacking in most studies, and human comparator groups are often small

4.  Future studies should diminish risk of bias, enhance real world clinical relevance, improve reporting and transparency, and appropriately temper conclusions
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